S&P 500   4,023.89
DOW   32,196.66
QQQ   301.94
S&P 500   4,023.89
DOW   32,196.66
QQQ   301.94
S&P 500   4,023.89
DOW   32,196.66
QQQ   301.94
S&P 500   4,023.89
DOW   32,196.66
QQQ   301.94
NYSE:HIMS

Hims & Hers Health (HIMS) Stock Forecast, Price & News

$3.45
+0.25 (+7.81%)
(As of 05/13/2022 06:40 PM ET)
Add
Compare
Today's Range
$3.30
$3.67
50-Day Range
$3.11
$5.51
52-Week Range
$2.72
$15.55
Volume
4.04 million shs
Average Volume
2.33 million shs
Market Capitalization
$707.50 million
P/E Ratio
N/A
Dividend Yield
N/A
Beta
0.38
30 days | 90 days | 365 days | Advanced Chart
Receive HIMS News and Ratings via Email

Sign-up to receive the latest news and ratings for Hims & Hers Health and its competitors with MarketBeat's FREE daily newsletter.

Hims & Hers Health logo

About Hims & Hers Health

Hims & Hers Health, Inc. operates a multi-specialty telehealth platform that connects consumers to licensed healthcare professionals. The company offers a range of health and wellness products and services available to purchase on its websites and mobile application directly by customers. It also provides prescription medication on a recurring basis and ongoing care from healthcare providers; and over-the-counter drug and device products, cosmetics, and supplement products, primarily focusing on wellness, sexual health and wellness, skincare, and hair care. The company's curated non-prescription products include vitamin C, melatonin, biotin, and collagen protein supplements in the wellness category; moisturizer, serums, and face wash in the skincare category; condoms, climax delay spray and wipes, vibrators, and lubricants in the sexual health and wellness category; and shampoos, conditioners, scalp scrubs, and topical treatments, such as minoxidil in the hair care category. In addition, it offers medical consultation services, as well as health and wellness products through wholesale partners. The company is based in San Francisco, California.

Headlines

See More Headlines

Industry, Sector and Symbol

Industry
Offices & clinics of medical doctors
Sub-Industry
N/A
Sector
Medical
Fax
N/A
Employees
398
Year Founded
N/A

Sales & Book Value

Annual Sales
$271.88 million
Book Value
$1.60 per share

Profitability

Net Income
$-107.66 million
Pretax Margin
-23.57%

Debt

Price-To-Earnings

Miscellaneous

Free Float
115,456,000
Market Cap
$707.50 million
Optionable
Optionable

Company Calendar

Last Earnings
5/09/2022
Today
5/16/2022
Next Earnings (Estimated)
8/10/2022
Fiscal Year End
12/31/2022

MarketRank

Overall MarketRank

1.98 out of 5 stars

Medical Sector

615th out of 1,403 stocks

Offices & Clinics Of Medical Doctors Industry

6th out of 13 stocks

Analyst Opinion: 3.3Community Rank: 2.7Dividend Strength: 0.0Insider Behavior: 3.3Valuation: 0.6 5 -4 -3 -2 -1 -













Hims & Hers Health (NYSE:HIMS) Frequently Asked Questions

Is Hims & Hers Health a buy right now?

7 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Hims & Hers Health in the last twelve months. There are currently 3 hold ratings and 4 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "buy" Hims & Hers Health stock.
View analyst ratings for Hims & Hers Health
or view top-rated stocks.

When is Hims & Hers Health's next earnings date?

Hims & Hers Health is scheduled to release its next quarterly earnings announcement on Wednesday, August 10th 2022.
View our earnings forecast for Hims & Hers Health
.

How were Hims & Hers Health's earnings last quarter?

Hims & Hers Health, Inc. (NYSE:HIMS) issued its quarterly earnings results on Monday, May, 9th. The company reported ($0.08) earnings per share for the quarter, hitting analysts' consensus estimates of ($0.08). The business had revenue of $101.30 million for the quarter, compared to the consensus estimate of $90.99 million. Hims & Hers Health had a negative net margin of 22.60% and a negative trailing twelve-month return on equity of 22.41%. Hims & Hers Health's quarterly revenue was up 93.7% on a year-over-year basis. During the same period last year, the company posted ($0.14) earnings per share.
View Hims & Hers Health's earnings history
.

What guidance has Hims & Hers Health issued on next quarter's earnings?

Hims & Hers Health updated its second quarter 2022 earnings guidance on Monday, May, 16th. The company provided EPS guidance of for the period. The company issued revenue guidance of $103.00 million-$106.00 million, compared to the consensus revenue estimate of $92.45 million.

What price target have analysts set for HIMS?

7 analysts have issued 12-month price objectives for Hims & Hers Health's stock. Their forecasts range from $6.00 to $16.00. On average, they expect Hims & Hers Health's share price to reach $9.43 in the next twelve months. This suggests a possible upside of 173.3% from the stock's current price.
View analysts' price targets for Hims & Hers Health
or view top-rated stocks among Wall Street analysts.

Who are Hims & Hers Health's key executives?
Hims & Hers Health's management team includes the following people:
  • Mr. Andrew Dudum, Co-Founder, Director & CEO (Age 33, Pay $627.39k) (LinkedIn Profile)
  • Ms. Melissa Baird, Chief Operations Officer (Age 44, Pay $535.57k) (LinkedIn Profile)
  • Mr. Yemi Okupe, Chief Financial Officer
  • Ms. Irene A. Becklund, Principal Accounting Officer (Age 37)
  • Ms. Soleil Teubner Boughton, Chief Legal Officer & Corp. Sec. (Age 43)
  • Ms. Amee Parekh, Sr. VP of HR
  • Mr. Mike Chi, Chief Growth Officer
  • Mr. Jonathan Spitzer C.F.A., Sr. VP of Investor Relations
  • Dr. Aimee Paik FAAD, M.D., Sr. VP & Member of Medical Advisory Board
  • Dr. Peter Stahl M.D., Sr. VP & Member of Medical Advisory Board
What is Hims & Hers Health's stock symbol?

Hims & Hers Health trades on the New York Stock Exchange (NYSE) under the ticker symbol "HIMS."

Who are Hims & Hers Health's major shareholders?

Hims & Hers Health's stock is owned by many different retail and institutional investors. Top institutional shareholders include Vanguard Group Inc. (4.43%), BlackRock Inc. (1.11%), Renaissance Technologies LLC (0.82%), Charles Schwab Investment Management Inc. (0.30%), Landscape Capital Management L.L.C. (0.27%) and Blueshift Asset Management LLC (0.18%). Company insiders that own Hims & Hers Health stock include Andrew Dudum, David B Wells, David B Wells, Jack Abraham, Lynne Chou O'keefe, Melissa Baird, Patrick Harrison Carroll, Soleil Boughton and Spencer Lee.
View institutional ownership trends for Hims & Hers Health
.

Which major investors are selling Hims & Hers Health stock?

HIMS stock was sold by a variety of institutional investors in the last quarter, including Vanguard Group Inc., GSA Capital Partners LLP, Group One Trading L.P., Hamilton Lane Advisors LLC, JPMorgan Chase & Co., Mirae Asset Global Investments Co. Ltd., BlackRock Inc., and Qube Research & Technologies Ltd. Company insiders that have sold Hims & Hers Health company stock in the last year include Andrew Dudum, Jack Abraham, Lynne Chou O'keefe, Melissa Baird, Patrick Harrison Carroll, Soleil Boughton, and Spencer Lee.
View insider buying and selling activity for Hims & Hers Health
or view top insider-selling stocks.

Which major investors are buying Hims & Hers Health stock?

HIMS stock was acquired by a variety of institutional investors in the last quarter, including Renaissance Technologies LLC, Landscape Capital Management L.L.C., Blueshift Asset Management LLC, Ergoteles LLC, Catalyst Capital Advisors LLC, Russell Investments Group Ltd., Legacy Advisors LLC, and Gerber Kawasaki Wealth & Investment Management. Company insiders that have bought Hims & Hers Health stock in the last two years include Andrew Dudum, and David B Wells.
View insider buying and selling activity for Hims & Hers Health
or or view top insider-buying stocks.

How do I buy shares of Hims & Hers Health?

Shares of HIMS can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Hims & Hers Health's stock price today?

One share of HIMS stock can currently be purchased for approximately $3.45.

How much money does Hims & Hers Health make?

Hims & Hers Health has a market capitalization of $707.50 million and generates $271.88 million in revenue each year. The company earns $-107.66 million in net income (profit) each year or ($0.360010) on an earnings per share basis.

How many employees does Hims & Hers Health have?

Hims & Hers Health employs 398 workers across the globe.

What is Hims & Hers Health's official website?

The official website for Hims & Hers Health is www.forhims.com.

How can I contact Hims & Hers Health?

Hims & Hers Health's mailing address is 2269 CHESTNUT STREET SUITE 523, SAN FRANCISCO CA, 94123. The company can be reached via phone at 415-851-0195 or via email at [email protected].

This page was last updated on 5/16/2022 by MarketBeat.com Staff

Resources

Premium Research Tools

MarketBeat All Access subscribers can access stock screeners, the Idea Engine, data export tools, research reports, and other premium tools.

Discover All Access

Market Data and Calendars

Looking for new stock ideas? Want to see which stocks are moving? View our full suite of financial calendars and market data tables, all for free.

View Market Data

Investing Education and Resources

Receive a free world-class investing education from MarketBeat. Learn about financial terms, types of investments, trading strategies and more.

Financial Terms
Details Here
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau MarketBeat is rated as Great on TrustPilot

© American Consumer News, LLC dba MarketBeat® 2010-2022. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information | RSS Feeds

© 2022 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research.